HTG Molecular Diagnostics Announces Distribution Agreements

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM ), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products. 

“By expanding our distribution reach into these markets, we believe the availability of the HTG EdgeSeq system and assays will accelerate the adoption of molecular profiling using NGS,” stated Jean Claude Gerard, PhD, VP European Commercial Operations for HTG Molecular Diagnostics.  Dr. Gerard added, “Both Gamidor and Durviz are as passionate as we are at HTG about enabling precision medicine at the local level.”

Gamidor provides systems, chemicals, reagents and services in Israel, offering state-of-the-art diagnostic solutions to hospitals, health management systems and academic research institutes.  Durviz is a distributor of next-generation sequencing reagents and library preparation systems in Spain and Portugal.  

“These agreements serve to expand HTG's reach outside the United States and we see our agreements with Gamidor and Durviz as models for additional agreements with distributors in select global markets,” stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com .

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our business, including its ex‑U.S. expansion, the capabilities of our technology, the subject distributor agreements and their expected benefits to us, and ex‑U.S. market development, including the rate of adoption of NGS-based molecular profiling. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop, manufacture and commercialize molecular profiling products, commercializing our products through distributor relationships, and expansion of our ex‑U.S. commercial operations. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: jamar.ismail@westwicke.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: tjjohnson@htgmolecular.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 69

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 22

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 201

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading

Top 5 Most Recently Viewed Articles

New York Times: Strong Growth Ahead with Innovative Strategies

Updated Category News Views 103

New York Times Positioned for Future Profit Growth Recently, Deutsche Bank has taken a significant step by initiating coverage on shares of the New York Times (NYSE:NYT) with a promising Buy rating and a price target of $65.00. Their analysis highlights the media company's innovative digital-first subscription model and strong fundamentals as major drivers of growth and...

Continue Reading
Maximizing Opportunities in Today's Commercial Insurance Market

Updated Category News Views 151

Understanding the Current U.S. Commercial Insurance Landscape In today’s economic climate, U.S. commercial insurance buyers are navigating one of the most advantageous periods witnessed in recent years. Despite this promising environment, the looming uncertainties affecting the economy pose challenges that require careful consideration from both buyers and insurers...

Continue Reading
Understanding the Market Activity of Dowlais Group Plc Deals

Updated Category News Views 179

Key Information About Dowlais Group Plc This disclosure pertains to an exempt principal trader engaged in client-serving transactions involving Dowlais Group Plc, providing essential insights into the movements and transactions related to its shares. Notable Dealings by the Exempt Principal Trader As highlighted, important dealings regarding the ordinary shares of Dowlais...

Continue Reading
Golden State Dermatology's Smart Expansion into Los Altos

Updated Category News Views 20

Golden State Dermatology Welcomes Todd Anhalt The Bay Area’s dermatology landscape just got an intriguing development. Todd Anhalt, a veteran dermatologist with a track record as long as a roll of duct tape, has teamed up with Golden State Dermatology (GSD). This Los Altos partnership isn't just about slapping a new name on a door—it's a strategic move to bolster...

Continue Reading
Unlocking Tesla's Future: AI, Innovation, and Growth Strategies

Updated Category News Views 117

Tesla got itself into a tight spot back in the day, trading around 40% lower than its peak. Folks were already getting antsy about where the stock was heading—had to keep an eye on those quarterly delivery numbers. The car side of things? Over 80% of projected revenues for FY24 came straight from that segment, so if it tanked, so did the whole show. Tesla's Valuation...

Continue Reading